Cancel
Christopher Naftzger
Interim CEO, General Counsel and Corporate Secretary
@
Nabriva Therapeutics
23jjdu9399w.k5u3120w@w4616y6.xw3
Sign up to see email
Known information
- Re-joined Nabriva Therapeutics in September 2021
- Has more than 25 years of legal experience
- Previously served as General Counsel and Corporate Secretary of Krystal Biotech
- Was Vice President, Deputy General Counsel and Assistant Secretary at Nabriva Therapeutics before rejoining
- Served as Vice President, General Counsel, Chief Compliance Officer, and Secretary of Unilife Medical Solutions
- Held senior in-house counsel positions with Chesapeake Corporation and Koch Industries
- Was a corporate partner with Blank Rome LLP in Washington, DC
- Obtained his undergraduate degree from Hampden-Sydney College
- Received his law degree from the Willamette University College of Law
About Nabriva Therapeutics
Nabriva Therapeutics is a commercial-stage biopharmaceutical company specializing in the development of anti-infective agents for serious infections, with key products including XENLETA® and CONTEPO™.
Report inaccurate information
